Compare Enveric Biosciences Inc (ENVB) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while YieldMax TSLA Option Income Strategy ETF trades at $22.5 (market cap $697.51M). The key difference: YieldMax TSLA Option Income Strategy ETF is far larger — about 102.6× Enveric Biosciences Inc's market cap, and YieldMax TSLA Option Income Strategy ETF is more actively traded (338,271 versus 64,867). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and YieldMax TSLA Option Income Strategy ETF for 43 Days on average.
| ENVB | TSLY | |
|---|---|---|
Market Cap | $6.80M | $697.51M |
Volume | 64,867 | 338,271 |
Sector | Health | Income / Options Overlay |
52-Week High | $10.80 | $43.35 |
52-Week Low | $1.27 | $20.49 |
Typical Hold Time | 14 Days | 43 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.48, down 1.0% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -235.48% and ROA at -193.53%, though it has beaten EPS expectations for four consecutive quarters. Recent developments include patent allowances for non-hallucinogenic therapeutics and positive preclinical data for EB-003.
While analyst consensus is 75% buy with no sell ratings, fundamental weaknesses in revenue generation and negative cash flow from operations pose significant risks. The stock's appeal hinges on clinical progress and regulatory milestones, making it suitable for risk-tolerant investors betting on biotech innovation amid high operational and financial volatility.
TSLY trades at $22.60, down 0.44% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.23, though recent analysis highlights concerns about capital erosion despite high yields. Technical indicators show support at $22 and resistance at $23, with neutral oscillators suggesting limited momentum.
While TSLY offers attractive income generation through its option income strategy, the fund faces structural limitations in capturing Tesla's upside potential. Recent downgrades to Hold reflect diminished return prospects amid Tesla's volatility changes. The primary risk remains the trade-off between high distributions and long-term capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
